

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin*. 2023 Jan;73(1):17–48.
3. International Agency for Research on Cancer. GLOBOCAN 2020. Indonesia - Global Cancer Observatory [Internet]. [cited 2023 Nov 23]. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
4. Zeng H, Ran X, An L, Zheng R, Zhang S, Ji JS, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study [Internet]. 2021. Available from: www.thelancet.com/public-health
5. Lofters AK, Gatov E, Lu H, Baxter NN, Guilcher SJT, Kopp A, et al. Lung cancer inequalities in stage of diagnosis in ontario, canada. *Current Oncology*. 2021 Jun 1;28(3):1946–56.
6. Bade BC, Dela Cruz CS. Lung cancer 2020: Epidemiology, etiology, and prevention. Vol. 41, *Clinics in Chest Medicine*. W.B. Saunders; 2020. p. 1–24.
7. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. *Lung Cancer*. 2014 Oct 1;86(1):78–84.
8. Ramadhaniah F, Khairina D, Sinulingga DT, Suzanna E, Mulawarman A. Gambaran pasien kanker paru di Rumah Sakit Kanker Dharmais (RSKD) tahun 2008-2012. *J Respir Indo*. 2019;39(1).
9. Qin Y, Zhang L, Liang X, Sun X, Wang N, Yuan M, et al. Venous and arterial thromboembolism in patients with metastatic lung cancer. *Clinical and Applied Thrombosis/Hemostasis*. 2023 Jan 1;29.
10. Goksel S, Ozcelik N. Distant metastasis patterns of lung cancer on positron emission tomography/computed tomography association with age and histological subtype. *Journal of the College of Physicians and Surgeons Pakistan*. 2021;31(12):1438–44.
11. Wang B, Chen S, Xiao H, Zhang J, Liang D, Shan J, et al. Analysis of risk factors and gene mutation characteristics of different metastatic sites of lung cancer. *Cancer Med*. 2022 Jan 1;11(1):268–80.
12. Costa GJ, de Mello MJG, Bergmann A, Ferreira CG, Thuler LCS. Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil. *Jornal Brasileiro de Pneumologia*. 2020;46(1).
13. Varlotto JM, Voland R, McKie K, Flickinger JC, DeCamp MM, Maddox D, et al. Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all

- lung patients and those with metastatic disease. *Cancer Med.* 2018 Apr 1;7(4):1211–20.
14. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Mol Clin Oncol.* 2015 Jan;3(1):217–21.
 15. WHO. Lung Cancer [Internet]. World Health Organization. 2023 [cited 2023 Oct 11]. Available from: <https://www.who.int/news-room/fact-sheets/detail/lung-cancer>
 16. Hondelink LM, Ernst SM, Atmodimedjo P, Cohen D, Wolf JL, Dingemans AMC, et al. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. *Eur J Cancer.* 2023 Mar 1;181:53–61.
 17. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. *J Cancer Res Clin Oncol.* 2020 Jan 1;146(1):43–52.
 18. Qin L, Yu X, Xu C, Liu Y. Prognostic impact of metastatic patterns and treatment modalities on overall survival in lung squamous cell carcinoma: A population-based study. *Medicine (United States).* 2023 Jul 21;102(29):E34251.
 19. Lin G, Qi K, Liu B, Liu H, Li J. A nomogram prognostic model for large cell lung cancer: Analysis from the Surveillance, Epidemiology and End Results Database. *Transl Lung Cancer Res.* 2021 Feb 1;10(2):622–35.
 20. Park HK, Han J, Kwon GY, Yeo MK, Bae GE. Patterns of extrathoracic metastasis in lung cancer patients. *Curr Oncol.* 2022 Nov 16;29(11):8794–801.
 21. Siddiqui F, Vaqar S, Siddiqui AH. Lung cancer [Internet]. StatPearls Publishing. 2022 [cited 2023 Mar 31]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482357/>
 22. Bryan S, Masoud H, Weir HK, Woods R, Lockwood G, Smith L, et al. Health Reports Cancer in Canada: Stage at diagnosis. Available from: www.statcan.gc.ca
 23. Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. *Cancer Epidemiology Biomarkers and Prevention.* 2019;28(10):1563–79.
 24. Vu T, Jin L, Datta PK. Effect of cigarette smoking on Epithelial to Mesenchymal Transition (EMT) in lung cancer. Vol. 5, *Journal of Clinical Medicine.* MDPI; 2016.
 25. Nasim F, Sabath BF, Eapen GA. Lung Cancer. Vol. 103, *Medical Clinics of North America.* W.B. Saunders; 2019. p. 463–73.
 26. Yang L, Fang F, Chan J, Chen B, Luo W, Zhu Q, et al. Metastatic patterns and prognosis of young lung cancer patients: a population-based study by age. *Ann Transl Med.* 2021 Jul;9(14):1159–1159.
 27. Wulandari L. Terapi personal sebagai upaya terobosan dalam pengobatan kanker paru. Abadi A, editor. Surabaya: Airlangga University Press; 2022.

28. Valastyan S, Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Vol. 147, Cell. Elsevier B.V.; 2011. p. 275–92.
29. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Vol. 5, Signal Transduction and Targeted Therapy. Springer Nature; 2020.
30. Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, et al. Circulating tumor cells in the early detection of human cancers. *Int J Biol Sci.* 2022;18(8):3251–65.
31. Fabricius HÅ, Starzonek S, Lange T. The role of platelet cell surface p-selectin for the direct platelet-tumor cell contact during metastasis formation in human tumors. Vol. 11, Frontiers in Oncology. Frontiers Media S.A.; 2021.
32. Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Vol. 32, Cancer Cell. Cell Press; 2017. p. 282–93.
33. Kacmarek RM, Stoller JK, Heuer AJ. Egan's fundamentals of respiratory care. 11th ed. Elsevier Health Sciences; 2016.
34. Komite Penanggulangan Kanker Nasional. Kanker paru. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
35. Betancourt Cuellar SL, Marom EM, Erasmus JJ. Imaging lung cancer. In: Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH, editors. Lung Cancer. 4th ed. New Jersey: Wiley Blackwell; 2014.
36. Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Vol. 22, International Journal of Molecular Sciences. MDPI AG; 2021.
37. Jain D, Roy-Chowdhuri S. Molecular pathology of lung cancer cytology specimens a concise review. Vol. 142, Archives of Pathology and Laboratory Medicine. College of American Pathologists; 2018. p. 1127–33.
38. Kutob L, Schneider F. Lung cancer staging. Vol. 13, Surgical Pathology Clinics. W.B. Saunders; 2020. p. 57–71.
39. Tanoue LT. Lung cancer staging. Vol. 41, Clinics in Chest Medicine. W.B. Saunders; 2020. p. 161–74.
40. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, et al. Diagnostic, predictive and prognostic biomarkers in non-small cell lung cancer (Nslc) management. Vol. 11, Journal of Personalized Medicine. MDPI; 2021.
41. Zheng M. Classification and pathology of lung cancer. Vol. 25, Surgical Oncology Clinics of North America. W.B. Saunders; 2016. p. 447–68.
42. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Vol. 94, Mayo Clinic Proceedings. Elsevier Ltd; 2019. p. 1623–40.
43. Kumar V, Abbas AK, Aster JC. Robbins and cotran pathologic basis of diseases. 9th edition. Amsterdam: Elsevier; 2015.
44. Lee DS, Kim YS, Kay CS, Kim SH, Yeo CD, Kim JW, et al. Distinctive patterns of initially presenting metastases and clinical outcomes according

- to the histological subtypes in stage IV non-small cell lung cancer. *Medicine (United States)*. 2016 Feb 1;95(6).
45. Rizki Ananda R, Ermayanti S, Abdiana. Hubungan staging kanker paru dengan skala nyeri pada pasien kanker paru yang dirawat di Bagian Paru RSUP DR M Djamil Padang [Internet]. Vol. 7, *Jurnal Kesehatan Andalas*. 2018. Available from: <http://jurnal.fk.unand.ac.id>
 46. Tarida Yuniar Sinaga F, Oktobiannobel J, Ariza Soeprihatini Soemarwoto R, Yunanda V. Description of progressivity and prognosis in lung cancer patients, 2018-2021. *méd prof j of Lampung [Internet]*. 2022 Aug 13 [cited 2024 Feb 4];12(2):336-41. Available from: <https://www.journalofmedula.com/index.php/medula/article/view/366>
 47. Pritami AA, Ariza Soeprihatini Soemarwoto R, Wintoko R. Faktor risiko kanker paru: Tinjauan pustaka. 2022.
 48. Mederos N, Friedlaender A, Peters S, Addeo A. Gender-specific aspects of epidemiology, molecular genetics and outcome: Lung cancer. Vol. 5, *ESMO Open*. BMJ Publishing Group; 2020.
 49. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Vol. 7, *Translational Lung Cancer Research*. AME Publishing Company; 2018. p. 220–33.
 50. Tahir MFIH. Karakteristik penderita kanker paru primer periode Januari 2017 – Desember 2019. Universitas Hasanuddin; 2020.
 51. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Vol. 25, *Wspolczesna Onkologia*. Termedia Publishing House Ltd.; 2021. p. 45–52.
 52. Purnamawati P, Tandrian C, Sumbayak EM, Kertadjaja W. Tinjauan pustaka: Analisis kejadian kanker paru primer di Indonesia pada tahun 2014-2019. *Jurnal Kedokteran Meditek*. 2021 Jun 25;27(2):164–72.
 53. Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G. Trends and characteristics of young non-small cell lung cancer patients in the United States. *Front Oncol*. 2015;5(MAY).
 54. ALQudah MA, ALFaqih MA, Hamouri S, Al-Shaikh AF, Haddad HK, Al-Quran WY, et al. Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study. *Annals of Medicine and Surgery*. 2021 May 1;65.
 55. Vardanjani H, Zeinali M, Radmerikhi S, Hadipour M. Lung cancer prevalence in iran by histologic subtypes. *Adv Biomed Res*. 2017;6(1):111.
 56. Houston KA, Mitchell KA, King J, White A, Ryan BM. Histologic lung cancer incidence rates and trends vary by race/ethnicity and residential county. *Journal of Thoracic Oncology*. 2018 Apr 1;13(4):497–509.
 57. Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, et al. Cigarette filter ventilation and its relationship to increasing rates of lung adenocarcinoma. Vol. 109, *Journal of the National Cancer Institute*. Oxford University Press; 2017.

58. Rudy Chairuddin M, Anang Marhana I, Erawati D. Profil pasien kanker paru primer yang dirawat inap dan dirawat jalan di Rumah Sakit Umum Daerah Dr Soetomo Surabaya. *Jurnal Respirasi*. 2019;5.
59. Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. *J Thorac Dis*. 2011;3(3):183–8.
60. Febriani A, Furqon A. Metastasis kanker paru. *Jurnal Respirasi*. 2018 Sep;Vol. 4.
61. WANG RA, LU YY, FAN DM. Reasons for cancer metastasis: A holistic perspective. *Mol Clin Oncol*. 2015 Nov;3(6):1199–202.
62. Agalioti T, Giannou AD, Stathopoulos GT. Pleural involvement in lung cancer. Vol. 7, *Journal of Thoracic Disease*. Pioneer Bioscience Publishing; 2015. p. 1021–30.
63. Popper HH. Progression and metastasis of lung cancer. *Cancer and Metastasis Reviews*. 2016 Mar 1;35(1):75–91.
64. Fick CN, Dunne EG, Lankadasari MB, Mastrogiacomo B, Asao T, Vanstraelen S, et al. Genomic profiling and metastatic risk in early-stage non-small cell lung cancer. Vol. 16, *JTCVS Open*. Elsevier B.V.; 2023. p. 9–16.

